ReproNovo raises USD 65 million to advance trials in reproductive health

Lausanne-based biotech ReproNovo has secured USD 65 million to advance Phase 2 trials for novel therapies in male infertility and women’s reproductive health.

ReproNovo, a biopharmaceutical company focused on reproductive medicine and women’s health, has raised USD 65 million in a Series A financing round. Headquartered in Lausanne, with development operations in Copenhagen and Barcelona, the company aims to address critical gaps in fertility treatments through the advancement of two Phase 2-ready clinical programs.

The financing round was led by Jeito Capital and co-led by AXA IM Alts and M Ventures, with additional support from Ysios Capital and ALSA Ventures. The funds will support ongoing clinical development and scale-up efforts, particularly for ReproNovo’s two lead candidates: RPN-001 and RPN-002.

RPN-001 (leflutrozole) is an orally administered therapy being developed to treat infertility in men with low serum testosterone, a condition affecting an increasing number of men, including younger populations. The treatment offers a novel approach by inhibiting aromatase activity and restoring testosterone levels. With male reproductive health now considered a global public health concern, the need for effective and accessible therapies has never been greater.

RPN-002 (nolasiban) is a first-in-class oxytocin receptor antagonist targeting adenomyosis, a debilitating gynecological condition associated with severe pain and reduced fertility. RPN-002 also holds potential to improve embryo implantation success rates in assisted reproductive technology (ART) procedures, a key area of need in women’s fertility treatment. No approved drugs currently exist for either indication.

Founded in 2021, ReproNovo is led by CEO Jean Marie Duvall, CSO & CMO Dr. Joan-Carles Arce, and CFO BingMei Hao. The leadership team brings extensive experience in reproductive medicine and drug development, with a history of successful clinical programs and commercial launches. With backing from a strong international syndicate, ReproNovo is well-positioned to expand its clinical footprint and bring its therapies closer to market.